- Home
- CVSA vs HAE Comparison
CVSA vs HAE Comparison
Compare CVSA & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVSA | HAE |
|---|---|---|
| Founded | 1987 | 1971 |
| Country | United States | United States |
| Employees | 4996 | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.8B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | CVSA | HAE |
|---|---|---|
| Price | $129.11 | $84.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $150.00 | $84.13 |
| AVG Volume (30 Days) | 323.7K | ★ 623.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $9.66 | N/A |
| Revenue Next Year | $6.58 | $5.23 |
| P/E Ratio | ★ N/A | $41.65 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $96.08 | $47.32 |
| 52 Week High | $135.96 | $88.59 |
Technical Indicators
Market Signals| Indicator | CVSA | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 67.14 |
| Support Level | $115.79 | $78.87 |
| Resistance Level | $133.69 | $86.72 |
| Average True Range (ATR) | 5.44 | 2.30 |
| MACD | 1.14 | 0.43 |
| Stochastic Oscillator | 80.57 | 72.09 |
Price Performance
Historical ComparisonAbout CVSA Covista Inc. Common Shares
Covista Inc is an American healthcare educator, serving more than 97,000 students and supported by a community of alumni across five accredited institutions. Through personalized, tech-enabled education powered by faculty and colleagues, it expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.